|
Pazopanib to suppress MET signaling in patients with refractory advanced solid tumors. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Patents, Royalties, Other Intellectual Property - patent held by US Government |
|
|
No Relationships to Disclose |
|
|
Patents, Royalties, Other Intellectual Property - Wayne St Univ, Cambridge Univ. Press |
|
|
Research Funding - Bristol-Myers Squibb (Inst); Dynavax Technologies (Inst) |
|
|
No Relationships to Disclose |